Second-Generation Anti-VEGF Therapies Lead DME and DR Management

January 29, 2026 Dr. Michael Lee – Health Editor Health

Okay, here’s a summary of the provided text:

Main Topic: Current management of Diabetic Retinopathy (DR) adn Diabetic Macular Edema (DME).

Key points:

* New Treatments: Second-generation anti-VEGF therapies like aflibercept 8 mg (Eylea HD) and faricimab (Vabysmo) are being used.
* Early Intervention: Early treatment of vision-threatening DME can prevent vision loss.
* Observation is Okay: Eyes with good vision and DME can be monitored until they show signs of worsening.
* Source: This information comes from a presentation by Sharon Fekrat, MD, at Retina 2026 in Waikoloa, Hawaii.
* Disclosures: Dr. Fekrat has financial ties to Regeneron (consulting) and Genentech (research funding).

In essence,the article highlights the evolving treatment landscape for diabetic eye diseases,emphasizing the importance of timely intervention and the availability of newer therapies.